Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-adjuvanted H5N1 vaccine schedules in adults
NCT00848029Phase 3
Key facts
- Status
- Completed
- Start
- Nov 2008
- Primary completion
- Jun 2009
- Countries
- 1
- Sponsor
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Drugs
- Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
- Conditions
- avian influenza (HPAI)
01
Overview
Phase 3, randomised, open-label trial of Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated) in avian influenza (HPAI), sponsored by Novartis. Started Nov 2008; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
The present study will evaluate the immunogenicity, safety and immunogenicity of two doses of monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult Subjects.
Beyond the preview
Go deeper on NCT00848029.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00848029.